Selected research
Market Outlook & Growth Opportunities
Global Topical Anti-infective Drugs Market Outlook and Growth Opportunities 2026
Market perspective
The global Topical Anti-infective Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Topical Anti-infective Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Topical Anti-infective Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Topical Anti-infective Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Topical Anti-infective Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Topical Anti-infective Drugs market include SK-SF, Zhejiang Funo Pharmaceuticals, Teva, Sun Pharmaceutical, Shandong Jingwei Pharmaceuticals, Sandoz, J & J, Liaoning Xingao Pharmaceuticals and Jiangsu Zhiyuan Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Topical Anti-infective Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Topical Anti-infective Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Topical Anti-infective Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Topical Anti-infective Drugs market.
Topical Anti-infective Drugs Segment by Company
SK-SF
Zhejiang Funo Pharmaceuticals
Teva
Sun Pharmaceutical
Shandong Jingwei Pharmaceuticals
Sandoz
J & J
Liaoning Xingao Pharmaceuticals
Jiangsu Zhiyuan Pharmaceuticals
Jiangsu Fubang Pharmaceuticals
Hubei Renfu
Bayer
STADA Arzneimittel
LEO Pharma
Kaken Pharmaceutical
Haleon
Glenmark Pharmaceuticals
Galderma
Bausch Health
Almirall
Topical Anti-infective Drugs Segment by Type
Ointment
Solution
Gel
Other
Topical Anti-infective Drugs Segment by Application
Hospital
Retail Phamracy
Other
Topical Anti-infective Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Topical Anti-infective Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Topical Anti-infective Drugs key companies, revenue, market share, and recent developments.
3. To split the Topical Anti-infective Drugs breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Topical Anti-infective Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Topical Anti-infective Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze Topical Anti-infective Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Topical Anti-infective Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Topical Anti-infective Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Topical Anti-infective Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Topical Anti-infective Drugs industry.
Chapter 3: Detailed analysis of Topical Anti-infective Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Topical Anti-infective Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Topical Anti-infective Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Ointment
- Solution
- Gel
- Other
Applications
- Hospital
- Retail Phamracy
- Other
Companies covered
- SK-SF
- Zhejiang Funo Pharmaceuticals
- Teva
- Sun Pharmaceutical
- Shandong Jingwei Pharmaceuticals
- Sandoz
- J & J
- Liaoning Xingao Pharmaceuticals
- Jiangsu Zhiyuan Pharmaceuticals
- Jiangsu Fubang Pharmaceuticals
- Hubei Renfu
- Bayer
- STADA Arzneimittel
- LEO Pharma
- Kaken Pharmaceutical
- Haleon
- Glenmark Pharmaceuticals
- Galderma
- Bausch Health
- Almirall
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Topical Anti-infective Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Topical Anti-infective Drugs Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Topical Anti-infective Drugs Market Dynamics
- 2.1 Topical Anti-infective Drugs Industry Trends
- 2.2 Topical Anti-infective Drugs Industry Drivers
- 2.3 Topical Anti-infective Drugs Industry Opportunities and Challenges
- 2.4 Topical Anti-infective Drugs Industry Restraints
3 Topical Anti-infective Drugs Market by Company
- 3.1 Global Topical Anti-infective Drugs Company Revenue Ranking in 2025
- 3.2 Global Topical Anti-infective Drugs Revenue by Company (2021-2026)
- 3.3 Global Topical Anti-infective Drugs Company Ranking (2024-2026)
- 3.4 Global Topical Anti-infective Drugs Company Manufacturing Base and Headquarters
- 3.5 Global Topical Anti-infective Drugs Company Product Type and Application
- 3.6 Global Topical Anti-infective Drugs Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Topical Anti-infective Drugs Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Topical Anti-infective Drugs Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Topical Anti-infective Drugs Market by Type
- 4.1 Topical Anti-infective Drugs Type Introduction
- 4.1.1 Ointment
- 4.1.2 Solution
- 4.1.3 Gel
- 4.1.4 Other
- 4.2 Global Topical Anti-infective Drugs Sales Value by Type
- 4.2.1 Global Topical Anti-infective Drugs Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Topical Anti-infective Drugs Sales Value by Type (2021-2032)
- 4.2.3 Global Topical Anti-infective Drugs Sales Value Share by Type (2021-2032)
5 Topical Anti-infective Drugs Market by Application
- 5.1 Topical Anti-infective Drugs Application Introduction
- 5.1.1 Hospital
- 5.1.2 Retail Phamracy
- 5.1.3 Other
- 5.2 Global Topical Anti-infective Drugs Sales Value by Application
- 5.2.1 Global Topical Anti-infective Drugs Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Topical Anti-infective Drugs Sales Value by Application (2021-2032)
- 5.2.3 Global Topical Anti-infective Drugs Sales Value Share by Application (2021-2032)
6 Topical Anti-infective Drugs Regional Value Analysis
- 6.1 Global Topical Anti-infective Drugs Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Topical Anti-infective Drugs Sales Value by Region (2021-2032)
- 6.2.1 Global Topical Anti-infective Drugs Sales Value by Region: 2021-2026
- 6.2.2 Global Topical Anti-infective Drugs Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Topical Anti-infective Drugs Sales Value (2021-2032)
- 6.3.2 North America Topical Anti-infective Drugs Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Topical Anti-infective Drugs Sales Value (2021-2032)
- 6.4.2 Europe Topical Anti-infective Drugs Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Topical Anti-infective Drugs Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Topical Anti-infective Drugs Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Topical Anti-infective Drugs Sales Value (2021-2032)
- 6.6.2 South America Topical Anti-infective Drugs Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Topical Anti-infective Drugs Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Topical Anti-infective Drugs Sales Value Share by Country, 2025 VS 2032
7 Topical Anti-infective Drugs Country-level Value Analysis
- 7.1 Global Topical Anti-infective Drugs Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Topical Anti-infective Drugs Sales Value by Country (2021-2032)
- 7.2.1 Global Topical Anti-infective Drugs Sales Value by Country (2021-2026)
- 7.2.2 Global Topical Anti-infective Drugs Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.7.2 France Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.14.2 China Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.17.2 India Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Topical Anti-infective Drugs Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Topical Anti-infective Drugs Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Topical Anti-infective Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 SK-SF
- 8.1.1 SK-SF Company Information
- 8.1.2 SK-SF Business Overview
- 8.1.3 SK-SF Topical Anti-infective Drugs Revenue and Gross Margin (2021-2026)
- 8.1.4 SK-SF Topical Anti-infective Drugs Product Portfolio
- 8.1.5 SK-SF Recent Developments
- 8.2 Zhejiang Funo Pharmaceuticals
- 8.2.1 Zhejiang Funo Pharmaceuticals Company Information
- 8.2.2 Zhejiang Funo Pharmaceuticals Business Overview
- 8.2.3 Zhejiang Funo Pharmaceuticals Topical Anti-infective Drugs Revenue and Gross Margin (2021-2026)
- 8.2.4 Zhejiang Funo Pharmaceuticals Topical Anti-infective Drugs Product Portfolio
- 8.2.5 Zhejiang Funo Pharmaceuticals Recent Developments
- 8.3 Teva
- 8.3.1 Teva Company Information
- 8.3.2 Teva Business Overview
- 8.3.3 Teva Topical Anti-infective Drugs Revenue and Gross Margin (2021-2026)
- 8.3.4 Teva Topical Anti-infective Drugs Product Portfolio
- 8.3.5 Teva Recent Developments
- 8.4 Sun Pharmaceutical
- 8.4.1 Sun Pharmaceutical Company Information
- 8.4.2 Sun Pharmaceutical Business Overview
- 8.4.3 Sun Pharmaceutical Topical Anti-infective Drugs Revenue and Gross Margin (2021-2026)
- 8.4.4 Sun Pharmaceutical Topical Anti-infective Drugs Product Portfolio
- 8.4.5 Sun Pharmaceutical Recent Developments
- 8.5 Shandong Jingwei Pharmaceuticals
- 8.5.1 Shandong Jingwei Pharmaceuticals Company Information
- 8.5.2 Shandong Jingwei Pharmaceuticals Business Overview
- 8.5.3 Shandong Jingwei Pharmaceuticals Topical Anti-infective Drugs Revenue and Gross Margin (2021-2026)
- 8.5.4 Shandong Jingwei Pharmaceuticals Topical Anti-infective Drugs Product Portfolio
- 8.5.5 Shandong Jingwei Pharmaceuticals Recent Developments
- 8.6 Sandoz
- 8.6.1 Sandoz Company Information
- 8.6.2 Sandoz Business Overview
- 8.6.3 Sandoz Topical Anti-infective Drugs Revenue and Gross Margin (2021-2026)
- 8.6.4 Sandoz Topical Anti-infective Drugs Product Portfolio
- 8.6.5 Sandoz Recent Developments
- 8.7 J & J
- 8.7.1 J & J Company Information
- 8.7.2 J & J Business Overview
- 8.7.3 J & J Topical Anti-infective Drugs Revenue and Gross Margin (2021-2026)
- 8.7.4 J & J Topical Anti-infective Drugs Product Portfolio
- 8.7.5 J & J Recent Developments
- 8.8 Liaoning Xingao Pharmaceuticals
- 8.8.1 Liaoning Xingao Pharmaceuticals Company Information
- 8.8.2 Liaoning Xingao Pharmaceuticals Business Overview
- 8.8.3 Liaoning Xingao Pharmaceuticals Topical Anti-infective Drugs Revenue and Gross Margin (2021-2026)
- 8.8.4 Liaoning Xingao Pharmaceuticals Topical Anti-infective Drugs Product Portfolio
- 8.8.5 Liaoning Xingao Pharmaceuticals Recent Developments
- 8.9 Jiangsu Zhiyuan Pharmaceuticals
- 8.9.1 Jiangsu Zhiyuan Pharmaceuticals Company Information
- 8.9.2 Jiangsu Zhiyuan Pharmaceuticals Business Overview
- 8.9.3 Jiangsu Zhiyuan Pharmaceuticals Topical Anti-infective Drugs Revenue and Gross Margin (2021-2026)
- 8.9.4 Jiangsu Zhiyuan Pharmaceuticals Topical Anti-infective Drugs Product Portfolio
- 8.9.5 Jiangsu Zhiyuan Pharmaceuticals Recent Developments
- 8.10 Jiangsu Fubang Pharmaceuticals
- 8.10.1 Jiangsu Fubang Pharmaceuticals Company Information
- 8.10.2 Jiangsu Fubang Pharmaceuticals Business Overview
- 8.10.3 Jiangsu Fubang Pharmaceuticals Topical Anti-infective Drugs Revenue and Gross Margin (2021-2026)
- 8.10.4 Jiangsu Fubang Pharmaceuticals Topical Anti-infective Drugs Product Portfolio
- 8.10.5 Jiangsu Fubang Pharmaceuticals Recent Developments
- 8.11 Hubei Renfu
- 8.11.1 Hubei Renfu Company Information
- 8.11.2 Hubei Renfu Business Overview
- 8.11.3 Hubei Renfu Topical Anti-infective Drugs Revenue and Gross Margin (2021-2026)
- 8.11.4 Hubei Renfu Topical Anti-infective Drugs Product Portfolio
- 8.11.5 Hubei Renfu Recent Developments
- 8.12 Bayer
- 8.12.1 Bayer Company Information
- 8.12.2 Bayer Business Overview
- 8.12.3 Bayer Topical Anti-infective Drugs Revenue and Gross Margin (2021-2026)
- 8.12.4 Bayer Topical Anti-infective Drugs Product Portfolio
- 8.12.5 Bayer Recent Developments
- 8.13 STADA Arzneimittel
- 8.13.1 STADA Arzneimittel Company Information
- 8.13.2 STADA Arzneimittel Business Overview
- 8.13.3 STADA Arzneimittel Topical Anti-infective Drugs Revenue and Gross Margin (2021-2026)
- 8.13.4 STADA Arzneimittel Topical Anti-infective Drugs Product Portfolio
- 8.13.5 STADA Arzneimittel Recent Developments
- 8.14 LEO Pharma
- 8.14.1 LEO Pharma Company Information
- 8.14.2 LEO Pharma Business Overview
- 8.14.3 LEO Pharma Topical Anti-infective Drugs Revenue and Gross Margin (2021-2026)
- 8.14.4 LEO Pharma Topical Anti-infective Drugs Product Portfolio
- 8.14.5 LEO Pharma Recent Developments
- 8.15 Kaken Pharmaceutical
- 8.15.1 Kaken Pharmaceutical Company Information
- 8.15.2 Kaken Pharmaceutical Business Overview
- 8.15.3 Kaken Pharmaceutical Topical Anti-infective Drugs Revenue and Gross Margin (2021-2026)
- 8.15.4 Kaken Pharmaceutical Topical Anti-infective Drugs Product Portfolio
- 8.15.5 Kaken Pharmaceutical Recent Developments
- 8.16 Haleon
- 8.16.1 Haleon Company Information
- 8.16.2 Haleon Business Overview
- 8.16.3 Haleon Topical Anti-infective Drugs Revenue and Gross Margin (2021-2026)
- 8.16.4 Haleon Topical Anti-infective Drugs Product Portfolio
- 8.16.5 Haleon Recent Developments
- 8.17 Glenmark Pharmaceuticals
- 8.17.1 Glenmark Pharmaceuticals Company Information
- 8.17.2 Glenmark Pharmaceuticals Business Overview
- 8.17.3 Glenmark Pharmaceuticals Topical Anti-infective Drugs Revenue and Gross Margin (2021-2026)
- 8.17.4 Glenmark Pharmaceuticals Topical Anti-infective Drugs Product Portfolio
- 8.17.5 Glenmark Pharmaceuticals Recent Developments
- 8.18 Galderma
- 8.18.1 Galderma Company Information
- 8.18.2 Galderma Business Overview
- 8.18.3 Galderma Topical Anti-infective Drugs Revenue and Gross Margin (2021-2026)
- 8.18.4 Galderma Topical Anti-infective Drugs Product Portfolio
- 8.18.5 Galderma Recent Developments
- 8.19 Bausch Health
- 8.19.1 Bausch Health Company Information
- 8.19.2 Bausch Health Business Overview
- 8.19.3 Bausch Health Topical Anti-infective Drugs Revenue and Gross Margin (2021-2026)
- 8.19.4 Bausch Health Topical Anti-infective Drugs Product Portfolio
- 8.19.5 Bausch Health Recent Developments
- 8.20 Almirall
- 8.20.1 Almirall Company Information
- 8.20.2 Almirall Business Overview
- 8.20.3 Almirall Topical Anti-infective Drugs Revenue and Gross Margin (2021-2026)
- 8.20.4 Almirall Topical Anti-infective Drugs Product Portfolio
- 8.20.5 Almirall Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst